Dan Rock is the Chief Scientific Officer at Cartography Biosciences; he serves as the lead of scientific operations, aligning future scientific strategies with the company’s mission and vision. Prior to Cartography, he was the Vice President of Pharmacokinetics, Dynamics, Metabolism and Bioanalytics at Merck where he was responsible for the design, optimization and translation of novel biologics and small molecules into the clinic. Dan completed his PhD studying physical chemistry at Washington State University. Outside of work, Dan spends time traveling with his family and bicycling.
Recent Posts
- Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
- Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
- Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team
- Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
- Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs
Recent Comments
No comments to show.